AUSTIN, TEXAS, August 29, 2016 – Siva Therapeutics (“Siva”) is pleased to announce that its Targeted Hyperthermia™ technology has been accepted has been accepted for characterization by the Nanotechnology Characterization Laboratory (NCL) in Frederick, Maryland. The NCL is a national resource which facilitates the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services, the NCL accelerates the transition of nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
The NCL’s core program is called the “assay cascade,” which characterizes nanoparticles’ physical attributes, their in vitro biological properties, and their in vivo compatibility using animal models. Approximately one year is required to characterize nanomaterials from receipt through the in vivo phase. Supported by the US Food and Drug Administration (FDA), the National Cancer Institute (NCI), and the National Institute of Standards and Technology (NIST), the NCL is a leader in the characterization of therapeutic nanoparticles.
“The NCL Assay Cascade Program is the premier program in the world for bringing nanomaterials through critical preclinical stages and facilitating regulatory review.” said Len Pagliaro, PhD, CEO of Siva. “We are honored and excited to be accepted into this prestigious program. The scientific, technical, and regulatory resources of the NCL will greatly strengthen Siva’s next steps toward the clinic.”
About Siva Therapeutics Inc
Siva Therapeutics Inc is developing a photothermal cancer therapy, Targeted Hyperthermia™, which uses heat to irreversibly damage solid tumor tissue. The heat is delivered to tumors by infrared light that is absorbed by SivaRods™ gold nanorods and re-emitted as heat. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be extremely safe, effective, and competitive in cost, and may provide a synergistic adjunct to drug therapy and other cancer treatments.
For more information please visit: www.sivatherapeutics.com
About the Nanotechnology Characterization Laboratory
The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the pre-clinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL is part of the National Cancer Institute Alliance for Nanotechnology in Cancer, and it serves as a national resource and knowledge base for cancer researchers, and facilitates the development and translation of nanoscale particles and devices for clinical applications. The activities within the NCL represent a formal scientific interaction of three Federal agencies: National Cancer Institute and U.S. Food and Drug Administration (FDA) of the Department of Health and Human Services, and National Institute of Standards and Technology (NIST) of the Department of Commerce. Scientists from each agency bring critical knowledge, experience, and skills needed to establish information to facilitate clinical technology development.
For more information please visit: http://ncl.cancer.gov/